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Background: Understanding the contextual factors that influence the dissemination and
implementation of evidence-based chronic disease prevention (EBCDP) interventions
in public health settings across countries could inform strategies to support the
dissemination and implementation of EBCDP interventions globally and more effectively
prevent chronic diseases. A survey tool to use across diverse countries is lacking. This
study describes the development and reliability testing of a survey tool to assess the stage
of dissemination, multi-level contextual factors, and individual and agency characteristics
that influence the dissemination and implementation of EBCDP interventions in Australia,
Brazil, China, and the United States.
Methods: Development of the 26-question survey included, a narrative literature review
of extant measures in EBCDP; qualitative interviews with 50 chronic disease prevention
practitioners in Australia, Brazil, China, and the United States; review by an expert panel
of researchers in EBCDP; and test-retest reliability assessment.
Results: A convenience sample of practitioners working in chronic disease prevention
in each country completed the survey twice (N = 165). Overall, this tool produced good
to moderately reliable responses. Generally, reliability of responses was higher among
practitioners from Australia and the United States than China and Brazil.
Conclusions: Reliability findings inform the adaptation and further development of this
tool. Revisions to four questions are recommended before use in China and revisions to
two questions before use in Brazil. This survey tool can contribute toward an improved
understanding of the contextual factors that public health practitioners in Australia,
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Brazil, China, and the United States face in their daily chronic disease prevention
work related to the dissemination and implementation of EBCDP interventions. This
understanding is necessary for the creation of multi-level strategies and policies that
promote evidence-based decision-making and effective prevention of chronic diseases
on a more global scale.
Keywords: chronic disease, reliability, evidence-based practice, implementation, international health
INTRODUCTION
Chronic diseases are a threat to global health, in developed
and developing countries alike, accounting for 60% of deaths
worldwide (1). The medical costs and loss of productivity related
to chronic diseases are a great financial burden to individuals
and economies (1). Evidence-based chronic disease prevention
(EBCDP) interventions are effective tools for preventing chronic
diseases (2). However, studies among U.S. and European public
health practitioners indicate that only 56–64% of chronic
disease prevention interventions currently in use are evidence-
based (3, 4), while estimates of use of EBCDP interventions
in lower and middle income countries are unknown. Studies
in Australia and the United States have identified multi-
level contextual factors that influence the dissemination and
implementation (D&I) of EBCDP interventions. Examples of
these contextual factors include individual- and agency-level
capacity characterized by the training, structure, material and
human resources at hand that hinder or facilitate the use of
EBCDP interventions (2, 5–7). Additional work has addressed
some of the contextual barriers by training practitioners on the
evidence-based decision-making process, specifically clarifying
the reasons for selecting EBCDP interventions and outlining
how to find the interventions and resources to support effective
implementation and quality improvement (3, 4, 7). These studies
report increases in the D&I of EBCDP interventions among
practitioners who attended the trainings. Research on Canadian
public health departments has identified tailored messaging as
an effective method for promoting the D&I of evidence-based
interventions (8), and examined the pathways through which
evidence is shared through organizational systems (9). These
contextually specific findings inform next steps in addressing
barriers and promoting evidence-based decision-making across
the Canada. Little is known about these contextual factors
that influence the D&I of EBCDP interventions in developing
countries, nor the similarities and differences of contextual
factors across countries. Several studies call for global strategies
to improve the D&I of EBCDP interventions in order to more
effectively reduce chronic diseases around the world (10–12).
Reviews of measures used to assess the contextual factors that
influence the D&I of EBCDP interventions highlight a lack
of psychometric testing of the existing measures and room
for improvement among those that have been tested (13–15).
To assess cross-country contextual factors and inform globally-
focused recommendations for facilitating the D&I of EBCDP
interventions, a single survey tool that can be used across
multiple, diverse countries is needed.
This study provides a detailed overview of the development
and test-retest reliability of a survey tool to measure the
stage of dissemination, multi-level contextual factors, and
individual and agency characteristics that influence the D&I
of EBCDP interventions in Australia, Brazil, China, and the
United States. These countries were chosen for several reasons
including, their leadership in distinct regions of the world
(16–20), differences on contextual variables of interest (e.g.,
sociocultural, political/economic) (21), and high prevalence of
chronic diseases (22). The World Health Organization reports
from 2014 showed that the large majority of deaths in each
of the four countries was due to chronic diseases (91% in
Australia, 88% in the United States, 87% in China, and 74%
in Brazil) (22). Further, based on the few studies of the
D&I of EBCDP from Brazil and China (23, 24), compared
with the many from Australia and the United States (25–29),
Brazil, and China were selected as countries likely in earlier




Development of the 26-question survey occurred in several
stages. First, a guiding framework was developed based on
previous work (30, 31) of the research team (see Figure 1).
This framework informed subsequent stages of survey tool
development, ensuring that qualitative interview questions and
initial survey drafts were literature-based and comprehensive
from the outset.
Second, a narrative literature review of extant measures in
EBCDP was carried out in order to identify relevant questions
and gaps in the D&I of EBCDP literature (2, 6, 31–35). Third,
between February and July 2015 semi-structured interviews
of public health practitioners in Australia (n = 13), Brazil
(n = 9), China (n = 16), and the United States (n = 12) were
conducted by trained researchers. Practitioners were identified
through purposive sampling based on their employment at
agencies responsible for the prevention of chronic disease in each
country, including community health services, regional health
departments, and non-government organizations (Australia);
the ministry of health and local health departments (Brazil);
hospitals, community health centers, and the Centers for Disease
Control and Prevention (China); and local health departments
(United States). The interviews were performed in English,
Chinese, or Portuguese, audio recorded, transcribed, translated
to English by two bi-lingual research team members (n = 25)
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FIGURE 1 | Factors affecting the stages of dissemination of evidence-based programs and policies for chronic disease prevention.
when appropriate, and analyzed using deductive, hierarchical
coding in NVivo version 10.
Forth, drafts of the survey underwent expert review by
13 chronic disease prevention researchers and were translated
forward and backward to Chinese and Portuguese from English.
Survey questions were organized into one of the five stages
of dissemination or as multi-level contextual factors seen
in Figure 1. Individual and agency characteristics were also
included. Seven response items were deemed non-applicable or
inappropriate for China contexts, but were included in the survey
for the other three countries. These response items and the
resulting tool can be found in Table 1.
Fifth, research teammembers in each country recruited public
health practitioners working in chronic disease prevention,
primarily on the local and regional levels, in each of the
four countries to complete the survey. Samples of practitioners
from various regions of each country were identified through
national databases and networks of chronic disease prevention
practitioners between November 2015 and April 2016. Public
health systems across countries varied so much that there was no
equivalent sampling method that worked for all four countries.
In the United States, a stratified (by region) random sample of
chronic disease prevention practitioners from a national database
received up to three emails and two follow-up telephone calls
requesting participation in the electronic survey (58% response
rate). In Australia, up to two emails requesting participation in
the electronic survey were sent to all chronic disease practitioners
in a national registry (18% response rate). In Brazil, the same
protocol as was followed in the United States was used, but with
an additional follow-up telephone call (46% response rate). In
China, a convenience sample of practitioners working within
a network of community hospitals received one email and
one follow-up telephone call requesting participation in the
electronic survey (87% response rate). All surveys were delivered
by an email embedded link and completed electronically. Upon
completion of the survey, all respondents were asked to re-
take the survey two to three weeks later for test-retest reliability
testing purposes. This process was repeated until each respondent
to the survey had been contacted twice, requesting them to
retake the survey. Calculating Cohen’s kappa and Intraclass
correlation coefficients (ICC) ranging from 0.50 to 0.70 require
a sample size of 25–50 test-retest pairs, respectively (38), thus
25 pairs were the minimum, but 50 pairs were the goal. During
data collection, political events in Brazil affected the work
lives of many Brazilian chronic disease practitioners and made
recruitment of Brazilian practitioners extraordinarily difficult
(39, 40). The data collection period was extended for research
team investigators in Brazil in order to reach the minimum
sample size.
This study was carried out in accordance with the committee
responsible for human experimentation (institutional and
national) and with the World Medical Association’s Declaration
of Helsinki with informed consent from all subjects. After
reading the electronic informed consent document, subjects
indicated their consent by selecting a radial button at the
bottom of the informed consent document that read, “I
consent to participate in this research study.” Additional written
documentation of consent was waived and the protocol was
approved by The University of Melbourne Human Ethics
Committee, Pontifica Universidade Catolica do Parana Research
Ethics Committee, The Hong Kong Polytechnic University
Human Ethics Committee of the Faculty of Health and Social
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TABLE 1 | Factors influencing the dissemination and implementation of evidence-based chronic disease prevention across four countries: a survey tool.
Questions Response options
Awareness
• Evidence-based public health is defined as: “the process of integrating
science-based interventions with community preferences to improve the health of
populations” (36).
1. With this definition in mind, how knowledgeable are you with evidence-based
processes? (select one)






Definition: Evidence-based interventions are those that several studies have found to
be effective at preventing chronic disease. Repositories are collections of
evidence-based interventions (e.g., Guide to Community Preventive Services) (US),
Health-Evidence.org (Australia), Cochrane Collaboration (US, Australia).
2. I have used repositories to find evidence-based interventions: (select one)
• In none of my programmatic areas
• In a few of my programmatic areas
• In many of my programmatic areas
• In all of my programmatic areas
3. Staff at my agency use repositories of evidence-based interventions:
(select one)
• In none of my programmatic areas
• In a few of my programmatic areas
• In many of my programmatic areas
• In all of my programmatic areas
4. When you make decisions about such things as program planning and
implementation, policy development, or funding, which of the following are important
to you? (select the top three)
• Support from leadership at my agency
• Support from elected officials
• Support from community partnerships
• Recommendations from the funding agency
• Colleagues are using the intervention
• Available resources (program dollars and staff)
• How easy the intervention or policy is to implement
• Evidence regarding the effectiveness of the intervention
• Health planning tools (e.g., MAPP or Health People 2010)
• Relevance of the intervention to the population of interest
• Seriousness of the health problem
• Other, please specify ______
• Not applicable
5. What avenues do you use to learn about the current study findings on







• Government agency staff
• Government reports
• Internet search engines
• Listservs/Newsletters/Online forums
• Media campaigns/Media interviews
• Networks





• Technical assistance/Data liaison
• Trainings/Workshops/Meetings within my agency
• Webinars
• Other, please specify ______
• None
6. For which avenues would you like additional access? (select all that apply) Same responses as #13
Implementation
7. Approximately what percentage of programs supported by your agency would you
say are evidence-based?
Fill in the blank 0–100%
8. As you think about the future, what is one thing you would change to help you
implement evidence-based chronic disease prevention interventions?
Fill in the blank
(Continued)
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TABLE 1 | Continued
Questions Response options
Maintenance
Quality improvement (QI) refers to ongoing formal assessments of the effectiveness
and quality of public health chronic disease prevention efforts. (37).
Some examples of quality improvement processes include: Results-based
accountability (RBA), Community Health Improvement Plan (CHIP),
Plan-Do-Study-Act (PDSA), and Plan-Do-Check-Act.
9. Staff at my agency use quality improvement processes: (select one)
• In none of my programmatic areas
• In a few of my programmatic areas
• In many of my programmatic areas
• In all of my programmatic areas
10. In your opinion, how often do programs end that should have continued? (i.e.,




11. When you think about public health programs that have ended, what are the
most common reasons for programs ending? (Select the top three)
• Program was never evaluated
• Program was evaluated but did not demonstrate impact
• Opposition/lack of support from leaders in my agency
• Opposition/lack of support from the general public
• Opposition/lack of support from policy makers
• Funding diverted to a higher priority program
• Grant funding ended
• Change in political leadership
• Insurance funding/coverage ended
• Program was adopted or continued by other organizations
• A program champion departed
• Program was not evidence-based
• Program was expensive
• Program was challenging to maintain
• Other, please specify ______
• I do not know
• Not applicable
12. In your opinion, how often do programs continue that should have ended? (i.e.,




13. When you think about public health programs that continued that should have
ended, what are the most common reasons for their continuation? (i.e., continue
without warrant) (Select the top three)
• Program was never evaluated
• Sustained support from leaders in your agency
• Sustained support from the general public
• Sustained support from policymakers
• Prohibitive costs of starting something new
• Absence of alternative options
• Sustained funding
• Presence of a program champion
• Program was considered evidence-based
• Program was low-cost
• Program was easy to maintain
• Other, please specify ______
• I do not know
• Not applicable
Contextual factors
14. Which of the following are personal barriers that make it harder for you to select
and implement evidence-based chronic disease prevention interventions? (Select all
that apply)
• Not being an expert on relevant issues
• Lack of confidence in finding data and statistics
• Lack of skills to develop evidence-based interventions
• Lack of confidence in carrying out evidence-based interventions
• Lack of decision-making authority
• Low value of evidence-based approaches
• Workload is too heavy/not enough time
• Overwhelmed by task
• Other, please specify ______
• None
15. Which of the following are agency-level barriers that make it harder for you to
select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)
• Poor understanding of evidence-based approaches
• Culture/climate is not supportive of change/new ideas
• No existing policies to support evidence-based approaches
• Agency does not provide training in evidence-based approaches
(Continued)
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TABLE 1 | Continued
Questions Response options
• Staff/leaders lack formal training in evidence-based approaches
• Lack of access to resources (e.g., computer, Internet)
• Not enough funding
• Low priority placed on chronic disease prevention
• No systems to ensure interventions are evidence-based
• Not enough staff
• Beliefs that evidence-based interventions are too difficult to
implement/sustain
• Other, please specify ______
• None
16. Which of the following are community-level barriers that make it harder for you to
select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)
• Lack of access to repositories/databases of scientific studies
• Lack of partnership between agency and community
• Community members’ needs compete with evidence-based
recommendations
• Catering to preferences of fundersa
• Low priority placed on chronic disease prevention
• Other, please specify ______
• None
17. Which of the following are sociocultural barriers that make it harder for you to
select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)
• Distrust of scientific data in the populations served
• Community cultural practices conflict with evidence-based
recommendations
• Not enough relevant evidence for populations served
• Serving a rural setting where data are lackinga
• Serving a highly disadvantaged population
• Serving a population that speaks a language different from the majoritya
• Evidence is presented in a language I do not understand
• Other, please specify ______
• None
18. Which of the following are political/economic barriers that make it harder for you
to select and implement evidence-based chronic disease prevention interventions?
(Select all that apply)
• Political leaders not providing enough support
• Funding changes that occur with changes in political leadership
• Political climate conflicts with evidence-based chronic disease prevention
recommendations
• Health care system does not support evidence-based chronic disease
prevention
• Other, please specify ______
• None
19. For which of the following skills would you like additional technical support or
training? (Check all that apply)
• Prioritizing program and policy options
• Quantifying the public health issue using descriptive epidemiology (e.g.,
concepts of person, place, time)
• Using quantitative evaluation approaches (e.g., surveillance or surveys)
• Using qualitative evaluation approaches (e.g., focus groups, key informant
interviews)
• Developing an action plan for achieving goals
• Defining the health issue according to the community’s needs and assets
• Adapting interventions for different communities and settings
• Using economic data in the decision making process
• Communicating research to policy makers
• Other, please specify ________
• None
Individual and agency characteristics
20. What is your gender? (select one) • Male
• Female
• Other
• Prefer not to answer




• 60 and over
• Prefer not to answer
(Continued)
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TABLE 1 | Continued
Questions Response options
22. What degree/credentials do you hold? (Check all that apply) • BS/BA
• CHES
• Certified Health Educator (in Diabetes, Asthma, etc.)
• RN or RD
• MS or MSc
• MPH or MSPH
• MA
• Other Master’s degree
• NP
• MO or DO
• PhD, DrPH, ScD
• Other, please specify ______
23. Though you may work in several capacities, how do you best describe your
primary position? (select one)
• Academic Researcher
• Academic Educator
• Community Health Nurse
• Department Head







• Program Planner/ Evaluator
• Public Health Specialist
• Social Worker
• Statistician
• Other, please specify ______






• I do not know











• I do not know
26. Is there anything else you would like to share on the topic of evidence-based
chronic disease prevention? Please specify
Fill in the blank
aThis item was not applicable and not included in the survey for respondents in China.
Science, and Washington University in St. Louis Institutional
Review Board.
Analyses
Test-retest reliability was examined on the survey questions,
excluding open-ended questions and individual and agency
characteristics. Intraclass correlation coefficients (ICC) were
calculated for questions with ordinal response options (questions
1 through 3, 9, 10, and 12; see Table 1). “I don’t know”
and “not applicable” response options were not included
in the ICC calculations. Each response item for questions
4, 5, 11, and 13 through 19 was dichotomized to reflect
whether a respondent selected the response option or not.
Cohen’s kappa was run for each of these response options
individually. The mean of all of the Cohen’s kappas for each
question’s set of response options was calculated. Cut-points
for ICC and mean kappa (excellent: ≥0.801; good: 0.601–0.80;
moderate: 0.401–0.60; poor: ≤0.40) were selected based on
recommendations (41, 42), and to aid in the interpretation of
the results. Percentage agreement was also calculated for all
of the aforementioned questions, excluding question 7, which
asked respondents to provide a percentage. Questions for which
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mean kappa was calculated, mean percentage agreement was
also calculated. Cut-points for percentage agreement included:
excellent: 89.5–100%; good: 74.5–89.4%; moderate: 60–74.4%;
and poor: <60%. All analyses were conducted in Stata
version 14.
RESULTS
There were 400 survey respondents total and 165 of them took
the survey twice for test-retest reliability purposes (N = 39
from Australia; N = 27 from Brazil; N = 45 from China;
N = 54 from the United States). The test-retest respondents
were all public health practitioners (e.g., nutritionist/dietician,
coordinator, community health nurse) working in chronic
disease prevention. Public Health Specialist was added as a
primary employment position option post hoc, in order to capture
a common “other” response provided by practitioners from
Brazil. Respondents were primarily female (79%) between 30
and 49 years old (53%). The mean survey completion time
varied by country, with Brazil having the longest (33.2min
± 27.8), followed by the United States (17.72min ± 13.4),
Australia (16.6min ± 10.0), and China (13.8min ± 10.5). The
mean number of days between test and retest was greatest in
Brazil (46.4 ± 28.5), followed by Australia (39.0 ± 2.8), China
(23.7 ± 7.6) and the United States (21.0 ± 9.1). Table 2 shows
frequency counts for each response option by country, the first
time respondents completed the survey. Item responses vary in
prevalence from zero endorsements to endorsement from a large
majority of a county’s sample.
The test-retest reliability coefficients and percentage
agreement by question and country appear in Table 3. Of
the seven questions with ordinal response options assessed using
ICC, six and seven demonstrated good to moderate reliability
among practitioners from Australia and the United States,
respectively, whereas three questions among practitioners from
Brazil and China demonstrated good to moderate reliability. Six
of those seven questions were also assessed using percentage
agreement. Six and five of the questions demonstrated good
to moderate percentage agreement among practitioners from
Australia and the United States, respectively, whereas three
questions among practitioners from Brazil and one among
practitioners from China demonstrated moderate percentage
agreement at best.
Of the 11 questions whose response options were
dichotomized and assessed using mean Cohen’s kappa, few
questions among practitioners across all four countries showed
moderate mean reliability at best (Australia, N = 2; Brazil,
N = 1; China, N = 1; United States, N = 3). Mean percentage
agreement told a different story for these 11 questions. All but
one question showed good mean percentage agreement among
practitioners from Australia and the United States. Seven and
five questions showed good mean percentage agreement among
practitioners from Brazil and China, respectively. The remaining
of the 11 questions across the countries showed moderate mean
percentage agreement.
The following four questions produced less than moderately
reliable responses based on both ICC and percentage agreement
among practitioners in China: Personal use of repositories to find
evidence-based interventions; Workplace staff use of repositories
to find evidence-based interventions; Frequency that programs
end that should have continued; and Frequency that programs
continue that should have ended. Two of those questions
(Workplace staff use of repositories to find evidence-based
interventions, and Frequency that programs end that should
have continued) produced less thanmoderately reliable responses
among practitioners from Brazil based on both measures of
reliability as well.
DISCUSSION
The development and reliability testing of this survey tool
are important early steps toward facilitating population-level
research that can increase our knowledge of country-specific
and cross-country contextual factors that influence the D&I
of EBCDP interventions and, in turn, begin to inform more
global strategies for improving the D&I of EBCDP. This study,
novel in its common methods across countries, showed that
the measurement tool produced moderate to good reliability of
responses, with at least one measure of reliability, among 14 of
the 18 questions across all four countries.
Reliability findings inform the adaptation and further
development of this tool. For example, the authors recommend
revising the four questions pertaining to personal and workplace
staff use of repositories for finding evidence-based interventions
and frequency that programs end or continue without warrant
before further use among practitioners in China and Brazil.
The poor reliability of responses produced from these questions
among practitioners from Brazil and China reflect a difference
in how they relate to the content of the questions, compared
with practitioners from Australia and the United States. This
difference may highlight meaningful differences within contexts
with respect to D&I processes and structures. For instance,
practitioners in countries for which EBCDP is in an earlier
stage of dissemination tend to be less knowledgeable about key
concepts of EBCDP, making the questions conceptually more
difficult and in turn negatively influencing the reliability of their
responses (43). Another potential contributing factor to the
lower reliability among responses from practitioners in Brazil
and China is that the survey tool had to be translated from
English to Chinese and Portuguese. Tanzer and Sim review
international guidelines on translating and adapting measures
across cultural contexts, and this study reflects well the best
practices for developing a relevant survey tool for use in the
four intended countries (44). For instance, bilingual researchers
from each of the four cultural perspectives, as well as public
health practitioners working in the chronic disease prevention
context in each country were involved in the development
of the questions, response options, translations, and reliability
testing. Despite steps that the research team took to minimize
mis-translation, the meaning of each question and response
option becomes one layer removed from its original, intended
meaning after translation. Next steps for informing further
adaptation of the survey tool should include validity testing
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TABLE 2 | Frequency of response option endorsement by country (N = 165).
Question and response options Australia
(Total N = 39)
Brazil
(Total N = 27)
China
(Total N = 45)
United States
(Total N = 54)
N (%) N (%) N (%) N (%)
1. How knowledgeable are you with evidence-based processes?
Not at all knowledgeable 0 (0.0) 0 (0.0) 7 (15.6) 0 (0.0)
Slightly knowledgeable 0 (0.0) 1 (3.7) 15 (33.3) 1 (1.9)
Somewhat knowledgeable 9 (23.1) 8 (29.6) 16 (35.6) 6 (11.1)
Moderately knowledgeable 22 (56.4) 13 (48.1) 8 (17.8) 31 (57.4)
Extremely knowledgeable 8 (20.5) 5( 18.5) 1 (2.2) 16 (29.6)
2. I have used repositories to find evidence-based interventions:
In none of my programmatic areas 2 (5.1) 0 (0.0) 12 (26.7) 3 (5.6)
In a few of my programmatic areas 11 (28.2) 7 (25.9) 25 (55.6) 18 (33.3)
In many of my programmatic areas 16 (41.0) 7 (25.9) 6 (13.3) 27 (50.0)
In all of my programmatic areas 8 (20.5) 13 (48.1) 1 (2.2) 5 (9.3)
I don’t know 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Not applicable 2 (5.13) 0 (0.0) 3 (6.7) 1 (1.9)
3. Staff at my agency use repositories of evidence-based interventions:
In none of their programmatic areas 0 (0.0) 0 (0.0) 11 (24.4) 2 (3.7)
In a few of their programmatic areas 9 (23.1) 5 (18.5) 19 (42.2) 18 (33.3)
In many of their programmatic areas 19 (48.7) 11 (40.7) 8 (17.8) 24 (44.4)
In all of their programmatic areas 4 (10.3) 9 (33.3) 0 (0.0) 1 (1.9)
I don’t know 3 (7.7) 1 (3.7) 9 (20.0) 7 (13.0)
Not applicable 3 (7.7) 1 (3.7) 0 (0.0) 2 (3.7)
4. When you make decisions about such things as program
planning and implementation, policy development, or funding,
which of the following are important to you?
Support from leadership at my agency 9 (23.1) 22 (81.5) 31 (68.9) 24 (44.4)
Support from elected officials 5 (12.8) 13 (48.1) 17 (37.8) 4 (7.4)
Support from community partnerships 13 (33.3) 20 (74.1) 16 (35.6) 21 (38.9)
Recommendations from the funding agency/ Recommendations
from the Research Management Department (China)
1 (2.6) 17 (63.0) 10 (22.2) 16 (29.6)
Colleagues are using the intervention 1 (2.6) 19 (70.4) 6 (13.3) 1 (1.9)
Available resources (program dollars and staff) 15 (38.5) 26 (96.3) 25 (55.6) 36 (66.7)
How easy the intervention or policy is to implement 2 (5.1) 12 (44.4) 23 (51.1) 1 (1.9)
Evidence regarding the effectiveness of the intervention 30 (76.9) 23 (85.2) 13 (28.9) 32 (59.3)
Health planning tools (e.g. MAPP or Health People
2010)/Government Health plans (China)
5 (12.8) 21 (77.8) 9 (20.0) 1 (1.9)
Relevance of the intervention to the population of interest 26 (66.7) 24 (88.9) 18 (40.0) 20 (37.0)
Seriousness of the health problem 9 (23.1) 20 (74.1) 9 (20.0) 5 (9.3)
Other 1 (2.6) 0 (0.0) 0 (0.0) 1 (1.9)
Not applicable 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0)
5. What avenues do you use to learn about the current study
findings on evidence-based chronic disease
prevention interventions?
Academic journals 36 (92.3) 19 (70.4) 23 (51.1) 24 (44.4)
Conferences 35 (89.7) 14 (51.9) 14 (31.1) 36 (66.7)
Email alerts 28 (71.8) 5 (18.5) 5 (11.1) 32 (59.3)
Evidence-based repositories 17 (43.6) 19 (70.4) 8 (17.8) 31 (57.4)
Facebook/Weibo, Wechat (China) 4 (10.3) 1 (3.7) 10 (22.2) 4 (7.4)
Fundersa 4 (10.3) 0 (0.0) – 23 (42.6)
Government agency staff 12 (30.8) 17 (63.0) 2 (4.4) 25 (46.3)
(Continued)
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TABLE 2 | Continued
Question and response options Australia
(Total N = 39)
Brazil
(Total N = 27)
China
(Total N = 45)
United States
(Total N = 54)
N (%) N (%) N (%) N (%)
Government reports 23 (59.0) 23 (85.2) 3 (6.7) 23 (42.6)
Internet search engines 21 (53.8) 16 (59.3) 14 (31.1) 32 (59.3)
Listservs/Newsletters/Online forums 15 (38.5) 2 (7.4) 3 (6.7) 25 (46.3)
Media campaigns/Media interviews 4 (10.3) 3 (11.1) 6 (13.3) 7 (13.0)
Networks 23 (59.0) 10 (37.0) 5 (11.1) 18 (33.3)
Partnerships (e.g., with universities, health departments,
professional associations)
26 (66.7) 14 (51.9) 7 (15.6) 35 (64.8)
Policy briefsa 11 (28.2) 12 (44.4) – 17 (31.5)
Press releases 8 (20.5) 3 (11.1) 6 (13.3) 9 (16.7)
Stakeholdersa 11 (28.2) 27 (100.0) – 14 (25.9)
Technical assistance/Data liaison 1 (2.6) 13 (48.1) 2 (4.4) 21 (38.9)
Trainings/Workshops/Meetings within my agency 17 (43.6) 11 (40.7) 18 (40.0) 7 (13.0)
Webinars 16 (41.0) 2 (7.4) 1 (2.2) 36 (66.7)
Other 0 (0.0) 2 (7.4) 0 (0.0) 1 (1.9)
None 1 (2.6) 1 (3.7) 5 (11.1) 0 (0.0)
6. For which avenues would you like additional access?
Academic journals 12 (30.8) 16 (59.3) 17 (37.8) 12 (22.2)
Conferences 8 (20.5) 17 (63.0) 10 (22.2) 16 (29.6)
Email alerts 3 (7.7) 5 (18.5) 10 (22.2) 4 (7.4)
Evidence-based repositories 13 (33.3) 7 (25.9) 19 (42.2) 18 (33.3)
Facebook/Weibo, Wechat (China) 2 (5.1) 2 (7.4) 12 (26.7) 3 (5.6)
Fundersa 4 (10.3) 3 (11.1) – 10 (18.5)
Government agency staff 6 (15.4) 2 (7.4) 2 (4.4) 6 (11.1)
Government reports 8 (20.5) 5 (18.5) 8 (17.8) 3 (5.6)
Internet search engines 1 (2.6) 2 (7.4) 11 (24.4) 3 (5.6)
Listservs/Newsletters/Online forums 4 (10.3) 3 (11.1) 14 (31.1) 8 (14.8)
Media campaigns/Media interviews 2 (5.1) 1 (3.7) 4 (8.9) 4 (7.4)
Networks 9 (23.1) 6 (22.2) 2 (4.4) 8 (14.8)
Partnerships (e.g., with universities, health departments,
professional associations)
13 (33.3) 11 (40.7) 13 (28.9) 15 (27.8)
Policy briefs 5 (12.8) 2 (7.4) 0 (0.0) 4 (7.4)
Press releases 2 (5.1) 2 (7.4) 7 (15.6) 2 (3.7)
Stakeholdersa 4 (10.3) 2 (7.4) – 3 (5.6)
Technical assistance/Data liaison 6 (15.4) 1 (3.7) 9 (20.0) 12 (22.2)
Trainings/Workshops/Meetings within my agency 8 (20.5) 10 (37.0) 18 (40.0) 12 (22.2)
Webinars 10 (25.6) 1 (3.7) 3 (6.7) 9 (16.7)
Other 3 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)
None 1 (2.6) 0 (0.0) 3 (6.7) 0 (0.0)
Questions 7 and 8 N/A
9. Staff at my agency use quality improvement processes:
In none of their programmatic areas 0 (0.0) 1 (3.7) 9 (20.0) 0 (0.0)
In a few of their programmatic areas 10 (25.6) 8 (29.6) 16 (35.6) 20 (37.0)
In many of their programmatic areas 16 (41.0) 12 (44.4) 15 (33.3) 28 (51.9)
In all of their programmatic areas 8 (20.5) 5 (18.5) 1 (2.2) 4 (7.4)
I don’t know 3 (7.7) 1 (3.7) 5 (11.1) 1 (1.9)
Not applicable 2 (5.1) 0 (0.0) 0 (0.0) 1 (1.9)
10. In your opinion, how often do programs end that should
have continued?
Never 2 (5.1) 21 (77.8) 21 (46.7) 0 (0.0)
(Continued)
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Question and response options Australia
(Total N = 39)
Brazil
(Total N = 27)
China
(Total N = 45)
United States
(Total N = 54)
N (%) N (%) N (%) N (%)
Sometimes 15 (38.5) 2 (7.4) 2 (4.4) 28 (51.9)
Often 20 (51.3) 3 (11.1) 19 (42.2) 24 (44.4)
11. When you think about public health programs that have
ended, what are the most common reasons for programs ending?
Program was never evaluated 9 (23.1) 9 (33.3) 3 (6.7) 9 (16.7)
Program was evaluated but did not demonstrate impact 12 (30.8) 8 (29.6) 16 (35.6) 7 (13.0)
Opposition/lack of support from leaders in my agency 7 (17.9) 10 (37.0) 8 (17.8) 6 (11.1)
Opposition/lack of support from the general public 1 (2.6) 6 (22.2) 20 (44.4) 6 (11.1)
Opposition/lack of support from policy makers 10 (25.6) 8 (29.6) 10 (22.2) 10 (18.5)
Funding diverted to a higher priority program 11 (28.2) 13 (48.1) 12 (26.7) 20 (37.0)
Grant funding ended 25 (64.1) 14 (51.9) 12 (26.7) 46 (85.2)
Change in political leadership 17 (43.6) 15 (55.6) 3 (6.7) 4 (7.4)
Insurance funding/coverage ended 1 (2.6) 4 (14.8) 0 (0.0) 6 (11.1)
Program was adopted or continued by other organizations 0 (0.0) 1 (3.7) 0 (0.0) 8 (14.8)
A program champion departed 9 (23.1) 9 (33.3) 3 (6.7) 1 (1.9)
Program was not evidence-based 1 (2.6) 7 (25.9) 5 (11.1) 3 (5.6)
Program was expensive 1 (2.6) 4 (14.8) 8 (17.8) 11 (20.4)
Program was challenging to maintain 2 (5.1) 4 (14.8) 24 (53.3) 2 (3.7)
Other, please specify ______ 2 (5.1) 0 (0.0) 1 (2.2) 2 (3.7)
I do not know 0 (0.0) 0 (0.0) 4 (8.9) 1 (1.9)
Not applicable 1 (2.6) 1 (3.7) 0 (0.0) 5 (9.3)
12. In your opinion, how often do programs continue that should
have ended?
Never 1 (2.6) 4 (14.8) 19 (42.2) 0 (0.0)
Sometimes 20 (51.3) 21 (77.8) 2 (4.4) 35 (64.8)
Often 10 (25.6) 2 (7.4) 22 (48.9) 13 (24.1)
13. When you think about public health programs that continued
that should have ended, what are the most common reasons for
their continuation?
Program was never evaluated 12 (30.8) 7 (25.9) 6 (13.3) 9 (16.7)
Sustained support from leaders in your agency 13 (33.3) 6 (22.2) 14 (31.1) 16 (29.6)
Sustained support from the general public 6 (15.4) 5 (18.5) 17 (37.8) 8 (14.8)
Sustained support from policymakers 11 (28.2) 12 (44.4) 15 (33.3) 21 (38.9)
Prohibitive costs of starting something new 9 (23.1) 4 (14.8) 5 (11.1) 5 (9.3)
Absence of alternative options 9 (23.1) 7 (25.9) 13 (28.9) 9 (16.7)
Sustained funding 7 (17.9) 12 (44.4) 14 (31.1) 26 (48.1)
Presence of a program champion 12 (30.8) 7 (25.9) 5 (11.1) 13 (24.1)
Program was considered evidence-based 4 (10.3) 2 (7.4) 9 (20.0) 5 (9.3)
Program was low-cost 9 (23.1) 6 (22.2) 5 (11.1) 11 (20.4)
Program was easy to maintain 10 (25.6) 6 (22.2) 12 (26.7) 15 (27.8)
Other, please specify ______ 4 (10.3) 1 (3.7) 0 (0.0) 4 (7.4)
I do not know 0 (0.0) 3 (11.1) 5 (11.1) 1 (1.9)
Not applicable 2 (5.1) 0 (0.0) 3 (6.7) 0 (0.0)
14. Which of the following are personal barriers that make it harder
for you to select and implement evidence-based chronic disease
prevention interventions?
Not being an expert on relevant issues 10 (25.6) 5 (18.5) 29 (64.4) 12 (22.2)
Lack of confidence in finding data and statistics 7 (17.9) 1 (3.7) 10 (22.2) 6 (11.1)
Lack of skills to develop evidence-based interventions 6 (15.4) 6 (22.2) 18 (40.0) 8 (14.8)
(Continued)
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TABLE 2 | Continued
Question and response options Australia
(Total N = 39)
Brazil
(Total N = 27)
China
(Total N = 45)
United States
(Total N = 54)
N (%) N (%) N (%) N (%)
Lack of confidence in carrying out evidence-based interventions 3 (7.7) 1 (3.7) 7 (15.6) 3 (5.6)
Lack of decision-making authority 23 (59.0) 8 (29.6) 20 (44.4) 15 (27.8)
Low value of evidence-based approaches 5 (12.8) 13 (48.1) 0 (0.0) 1 (1.9)
Workload is too heavy/not enough time 19 (48.7) 5 (18.5) 19 (42.2) 33 (61.1)
Overwhelmed by task 5 (12.8) 6 (22.2) 6 (13.3) 11 (20.4)
Other 8 (20.5) 1 (3.7) 1 (2.2) 12 (22.2)
None 2 (5.1) 0 (0.0) 0 (0.0) 5 (9.3)
15. Which of the following are agency-level barriers that make it
harder for you to select and implement evidence-based chronic
disease prevention interventions?
Poor understanding of evidence-based approaches 6 (15.4) 5 (18.5) 4 (8.9) 12 (22.2)
Culture/climate is not supportive of change/new ideas 14 (35.9) 3 (11.1) 1 (2.2) 20 (37.0)
No existing policies to support evidence-based approaches 5 (12.8) 4 (14.8) 14 (31.1) 9 (16.7)
Agency does not provide training in evidence-based approaches 9 (23.1) 10 (37.0) 5 (11.1) 10 (18.5)
Staff/leaders lack formal training in evidence-based approaches 12 (30.8) 7 (25.9) 13 (28.9) 14 (25.9)
Lack of access to resources (e.g., computer, Internet) 4 (10.3) 3 (11.1) 14 (31.1) 3 (5.6)
Not enough funding 22 (56.4) 13 (48.1) 13 (28.9) 40 (74.1)
Low priority placed on chronic disease prevention 5 (12.8) 5 (18.5) 4 (8.9) 12 (22.2)
No systems to ensure interventions are evidence-based 8 (20.5) 16 (59.3) 11 (24.4) 15 (27.8)
Not enough staff 11 (28.2) 4 (14.8) 17 (37.8) 30 (55.6)
Beliefs that evidence-based interventions are too difficult to
implement/sustain
4 (10.3) 2 (7.4) 4 (8.9) 4 (7.4)
Other 6 (15.4) 0 (0.0) 0 (0.0) 2 (3.7)
None 3 (7.7) 0 (0.0) 3 (6.7) 3 (5.6)
16. Which of the following are community-level barriers that make
it harder for you to select and implement evidence-based chronic
disease prevention interventions?
Lack of access to repositories/databases of scientific studies 7 (17.9) 4 (14.8) 37 (82.2) 7 (13.0)
Lack of partnership between agency and community 13 (33.3) 4 (14.8) 6 (13.3) 13 (24.1)
Community members’ needs compete with evidence-based
recommendations
22 (56.4) 8 (29.6) 20 (44.4) 30 (55.6)
Catering to preferences of fundersa 17 (43.6) 3 (11.1) – 25 (46.3)
Low priority placed on chronic disease prevention 11 (28.2) 14 (51.9) 7 (15.6) 15 (27.8)
Other 4 (10.3) 1 (3.7) 0 (0.0) 6 (11.1)
None 1 (2.6) 7 (25.9) 3 (6.7) 4 (7.4)
17. Which of the following are sociocultural barriers that make it
harder for you to select and implement evidence-based chronic
disease prevention interventions?
Distrust of scientific data in the populations served 2 (5.1) 5 (18.5) 7 (15.6) 13 (24.1)
Community cultural practices conflict with evidence-based
recommendations
20 (51.3) 9 (33.3) 13 (28.9) 19 (35.2)
Not enough relevant evidence for populations served 18 (46.2) 5 (18.5) 25 (55.6) 14 (25.9)
Serving a rural setting where data are lackinga 15 (38.5) 3 (11.1) – 34 (63.0)
Serving a highly disadvantaged population 18 (46.2) 7 (25.9) 10 (22.2) 21 (38.9)
Serving a population that speaks a language different from the
majoritya
7 (17.9) 1 (3.7) – 8 (14.8)
Evidence is presented in a language I do not understand 0 (0.0) 1 (3.7) 6 (13.3) 2 (3.7)
Other 1 (2.6) 8 (29.6) 1 (2.2) 2 (3.7)
None 3 (7.7) 2 (7.4) 4 (8.9) 4 (7.4)
(Continued)
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Question and response options Australia
(Total N = 39)
Brazil
(Total N = 27)
China
(Total N = 45)
United States
(Total N = 54)
N (%) N (%) N (%) N (%)
18. Which of the following are political/economic barriers that
make it harder for you to select and implement evidence-based
chronic disease prevention interventions?
Political leaders not providing enough support 24 (61.5) 10 (37.0) 26 (57.8) 21 (38.9)
Funding changes that occur with changes in political leadership 33 (84.6) 12 (44.4) 13 (28.9) 31 (57.4)
Political climate conflicts with evidence-based chronic disease
prevention recommendations
21 (53.8) 2 (7.4) 16 (35.6) 25 (46.3)
Health care system does not support evidence-based chronic
disease prevention
15 (38.5) 5 (18.5) 3 (6.7) 15 (27.8)
Other 5 (12.8) 3 (11.1) 0 (0.0) 2 (3.7)
None 1 (2.6) 0 (0.0) 12 (26.7) 5 (9.3)
19. For which of the following skills would you like additional
technical support or training:
Prioritizing program and policy options
6 (15.4) 17 (63.0) 20 (44.4) 16 (29.6)
Quantifying the public health issue using descriptive
epidemiology (e.g., concepts of person, place, time)
22 (56.4) 14 (51.9) 15 (33.3) 21 (38.9)
Using quantitative evaluation approaches (e.g., surveillance or
surveys)
18 (46.2) 4 (14.8) 14 (31.1) 20 (37.0)
Using qualitative evaluation approaches (e.g., focus groups, key
informant interviews)
15 (38.5) 6 (22.2) 11 (24.4) 19 (35.2)
Developing an action plan for achieving goals 13 (33.3) 13 (48.1) 19 (42.2) 17 (31.5)
Defining the health issue according to the community’s needs
and assets
12 (30.8) 17 (63.0) 26 (57.8) 27 (50.0)
Adapting interventions for different communities and settings 16 (41.0) 16 (59.3) 12 (26.7) 29 (53.7)
Using economic data in the decision making process 21 (53.8) 12 (44.4) 16 (35.6) 22 (40.7)
Communicating research to policy makers 20 (51.3) 8 (29.6) 15 (33.3) 23 (42.6)
Other 1 (2.6) 0 (0.0) 1 (2.2) 1 (1.9)
None 1 (2.6) 7 (25.9) 3 (6.7) 2 (3.7)
aThis item was not applicable and not included in the survey for respondents in China.
among chronic disease prevention practitioners in Australia,
Brazil, China, and the United States, ideally in representative
samples (45).
There was low prevalence (N < 5) for many response options
and the items with low prevalence varied by country. According
to Sim and Wright, low prevalence has stifling effects on Cohen’s
kappa coefficients, but inflating effects on percentage agreement
(46). Low prevalence likely contributed to the low kappa
coefficients and comparatively higher percentage agreement
found in this study. A larger sample of practitioners across all four
countries with more diversity of experiences may improve the
variability of responses and the accuracy of reliability findings.
Response items with low prevalence of endorsements may also
reflect response items that are less applicable to practitioners’
experiences in that particular country. Use of this survey tool in a
larger, randomly selected sample of chronic disease practitioners
in each country would clarify this conjecture.
Strengths and Limitations
This study responds well to a U.S. federal report that called for
additional research focused on the experiences and perspectives
of key stakeholders in evidence-based intervention delivery, in
order to better facilitate the sustainability of interventions (47).
The questions within this survey tool reflect critical contextual
factors based on the literature, qualitative interviews of public
health practitioners, and expert review (2, 5, 6). This survey
tool allows researchers to proceed with research on the D&I of
EBCDP interventions on a more global scale than was previously
available. To our knowledge, this is the first study of its kind
that used common methods across four countries. The research
team had particular trouble recruiting retest respondents in
Brazil due to significant political unrest that affected public
health practitioners at the time of the request (39, 40). This
contributed to the longer duration between test and retest and
the smaller sample from Brazil compared with the other three
countries. Additionally, his survey tool demonstrated lower
reliability of responses among practitioners from Brazil and
China compared with those fromAustralia and the United States.
Lastly, a convenience sampling approach was carried out in
some of the countries to recruit chronic disease prevention
practitioners serving local or regional jurisdictions. Such a
sampling method introduces potential selection bias and is
unlikely to produce representative samples of all chronic disease
prevention practitioners in each country. However, the intention
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%a ICCb,c % ICC % ICC % ICC
Personal knowledge of evidence-based processes 0.564 0.570 0.667 0.003 0.467 0.511 0.660 0.658
Personal use of repositories to find evidence-based
interventions
0.583 0.544 0.630 0.594 0.512 −0.007 0.571 0.508
Workplace staff use of repositories to find
evidence-based interventions
0.828 0.762 0.539 0.264 0.576 0.374 0.643 0.515
Percentage workplace programs are evidence-based – 0.731 – 0.566 – 0.797 – 0.797
Workplace staff use of quality improvement processes 0.581 0.422 0.539 0.423 0.600 0.601 0.600 0.544
Frequency that programs end that should have
continued
0.714 0.297 0.444 0.219 0.480 0.174 0.792 0.585
Frequency that programs continue that should have
ended

















Important factors in decision-making related to program
planning and implementation, policy development, or
funding
0.811 0.305 0.768 0.416 0.739 0.311 0.772 0.361
Avenues used to learn about evidence-based chronic
disease prevention interventions
0.774 0.402 0.702 0.297 0.804 0.225 0.786 0.408
Avenues for which additional access is needed 0.810 0.214 0.763 0.154 0.800 0.252 0.778 0.177
Most common reasons for program termination 0.824 0.203 0.693 0.203 0.745 0.179 0.840 0.269
Most common reasons for program continuation 0.758 0.258 0.684 0.219 0.733 0.133 0.754 0.249
Personal barriers to selecting and implementing
evidence-based chronic disease prevention interventions
0.823 0.379 0.810 0.308 0.749 0.336 0.857 0.376
Organizational barriers to selecting and implementing
evidence-based chronic disease prevention interventions
0.783 0.279 0.790 0.362 0.794 0.260 0.838 0.462
Community-level barriers to selecting and implementing
evidence-based chronic disease prevention interventions
0.747 0.235 0.763 0.337 0.836 0.367 0.798 0.387
Sociocultural barriers to selecting and implementing
evidence-based chronic disease prevention interventions
0.756 0.286 0.806 0.353 0.808 0.433 0.848 0.476
Political/economic barriers to selecting and
implementing evidence-based chronic disease
prevention interventions:
0.763 0.204 0.778 0.391 0.747 0.267 0.782 0.329
Skills for which additional technical support or training is
needed
0.764 0.466 0.619 0.191 0.687 0.257 0.736 0.273
a%, Percent agreement. b ICC, Intraclass correlation coefficient. cSurvey questions with ordinal response options were assessed using ICC. dSurvey questions with a list of response
options had each response option dichotomized into selected or not selected, then assessed using Cohen’s kappa, and the mean kappa for each set of response options is reported.
of the present study was not to test hypotheses or provide
prevalence estimates, which would have required using methods
to address sampling error (46). Acknowledging these limitations
of the sampling approach, the researcher team ensured that the
selected sample included practitioners from various regions of
each country, and provided distributions of all survey responses
as well as demographic characteristics of the sample.
CONCLUSION
This survey tool allows cross-country data collection that can
contribute toward an improved understanding of the contextual
factors that public health practitioners in Australia, Brazil,
China, and the United States face in their daily chronic
disease prevention work. This understanding is necessary for
the creation of multi-level strategies and policies that promote
evidence-based decision-making and effective prevention of
chronic diseases on a global scale.
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